Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of products for the aging population in Canada, the United States, and Europe. Its lead drug candidate is Fexapotide Triflutate (NX-1207) for the treatment of benign prostatic hyperplasia and low grade localized prostate cancer, as well as hepatocellular carcinoma. The company also offers NicAlert for detecting smoking status; and TobacAlert for detecting second-hand smoke exposure. In addition, it develops drugs for the treatment of Alzheimer’s disease. The company was founded in 1989 and is headquartered in Nassau, Bahamas.
तुलना करने के लिए मीट्रिक्स | NYMXF | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधNYMXFपीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | −2.7x | −2.2x | −0.6x | |
PEG अनुपात | 0.05 | −0.07 | 0.00 | |
क़ीमत/बुक | −7.5x | 0.1x | 2.6x | |
क़ीमत / एलटीएम बिक्री | - | 14.9x | 3.1x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 361.9% | 56.2% | |
उचित मूल्य अपसाइड | अनलॉक करें | 5.5% | 7.7% | अनलॉक करें |